Literature DB >> 16182497

Can we relate MeCP2 deficiency to the structural and chemical abnormalities in the Rett brain?

Dawna Duncan Armstrong1.   

Abstract

The mutated gene for Rett syndrome, MECP2, has now been identified in ninety percent of cases. Molecular biologists are immersed in the study of this gene's biology determining how its mutation could be responsible for such an enigmatic phenotype. In this paper the same question is considered, re-examining the structural phenotype of the Rett brain and asking; is MeCP2 present at the appropriate time and place in brain development to influence the structural and chemical abnormalities which characterize the Rett brain? Data from the literature and previous research suggest that MeCP2 is expressed during critical periods of brain development at several sites and in different neurons. It supports the idea that inadequate functioning of MeCP2 alters trophic factors and raises the possibility that replacement of these factors might improve brain function. The availability of mouse models now makes it possible to test such ideas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16182497     DOI: 10.1016/j.braindev.2004.10.009

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  7 in total

Review 1.  Transient receptor potential channels as novel effectors of brain-derived neurotrophic factor signaling: potential implications for Rett syndrome.

Authors:  Michelle D Amaral; Christopher A Chapleau; Lucas Pozzo-Miller
Journal:  Pharmacol Ther       Date:  2006-11-21       Impact factor: 12.310

Review 2.  Cardiac disease and Rett syndrome.

Authors:  M Acampa; F Guideri
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

3.  MECP2 impairs neuronal structure by regulating KIBRA.

Authors:  Alison A Williams; Robin White; Ashley Siniard; Jason Corneveaux; Matt Huentelman; Carsten Duch
Journal:  Neurobiol Dis       Date:  2016-03-22       Impact factor: 5.996

4.  F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome.

Authors:  Claudio De Felice; Cinzia Signorini; Thierry Durand; Camille Oger; Alexandre Guy; Valérie Bultel-Poncé; Jean-Marie Galano; Lucia Ciccoli; Silvia Leoncini; Maurizio D'Esposito; Stefania Filosa; Alessandra Pecorelli; Giuseppe Valacchi; Joussef Hayek
Journal:  J Lipid Res       Date:  2011-09-13       Impact factor: 5.922

5.  Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome.

Authors:  Lianne Robinson; Jacky Guy; Leanne McKay; Emma Brockett; Rosemary C Spike; Jim Selfridge; Dina De Sousa; Cara Merusi; Gernot Riedel; Adrian Bird; Stuart R Cobb
Journal:  Brain       Date:  2012-04-23       Impact factor: 13.501

6.  A mental retardation gene, motopsin/neurotrypsin/prss12, modulates hippocampal function and social interaction.

Authors:  Shinichi Mitsui; Yoji Osako; Fumiaki Yokoi; Mai T Dang; Kazunari Yuri; Yuqing Li; Nozomi Yamaguchi
Journal:  Eur J Neurosci       Date:  2009-12-10       Impact factor: 3.386

7.  Apoptotic Activity of MeCP2 Is Enhanced by C-Terminal Truncating Mutations.

Authors:  Alison A Williams; Vera J Mehler; Christina Mueller; Fernando Vonhoff; Robin White; Carsten Duch
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.